Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic ProgramsNEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr.

Patients with diabetes may not need to have a HbA1c value lower than 8% before cataract surgery to reduce the risk for endophthalmitis.

CONCLUSIONS This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

Managing Your Diabetes Can Help Prevent Associated Vision Loss Mar. 12, 2025 — Although there is no cure, diabetic retinal disease treatment has improved over the past two ... Minimal TV Viewing ...